We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Cgz4.5

Canagliflozin Research

Mostly mechanism / observational

162 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Canagliflozin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 2,573 participants.

Based on 162 studies · 22 meta-analyses · 131 RCTs · 860,331 total participants

Confidence

High confidence

By outcome

Glucose & weightLowers blood glucose via urinary glucose excretion (the approved diabetes effect) · Weeks to months
Mostly mechanism / observational109 studies
Cardiovascular & heart failureSGLT2 class reduces cardiovascular death, heart-failure hospitalization, and kidney-disease progression — including in non-diabetics · Months to years
Mostly mechanism / observational74 studies
Safety profile
Mostly mechanism / observational7 studies
Lifespan & aging (preclinical)
Mostly mechanism / observational3 studies

Active research area

64 studies in the last 5 years · Latest meta-analysis: 2026

201420202026

1Meta-Analysis2024

Wang N, Wu Z, Ren J, Zheng X, Han X · Clin Pharmacokinet (2024)

Canagliflozin Research

Mostly mechanism / observational

SGLT2 Inhibitors in Patients with Heart Failure: A Model-Based Meta-Analysis.

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.

Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.

Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.

SGLT2 inhibitors and lower limb complications: an updated meta-analysis.

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials.

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.

Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.

Endocrinology: What You May Have Missed in 2025

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis

A Systematic Review on Effect of Canagliflozin in Special Population.

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.

Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.